Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
Xingyu Chen, Lixiang Feng, Yujing Huang, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 104-104
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity
Lea Monteran, Nour Ershaid, Ye’ela Scharff, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1252-1275
Closed Access | Times Cited: 10
CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies
Zhipu Niu, Jingyuan Wu, Qiancheng Zhao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth
Anthony Cheung, Alicia M. Chenoweth, Annelie Johansson, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 15, pp. 3298-3315
Open Access | Times Cited: 10
NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation
Xuran Zhang, Ke An, Xin Ge, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 10
Tailored therapies for triple-negative breast cancer: current landscape and future perceptions
Yumna Khan, Sana Rizvi, Ali Raza, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 1
Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
Ling Tong, Xiangling Yu, Shan Wang, et al.
Breast Cancer Targets and Therapy (2023) Vol. Volume 15, pp. 647-658
Open Access | Times Cited: 14
MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer
Xin-Yi Sui, Shuo-Wen Cao, Xiao-Qing Song, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Unravelling the role of ubiquitin-specific proteases in breast carcinoma: insights into tumour progression and immune microenvironment modulation
Huiyuan Yang, Tingting Sun, Zhenni Sun, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: A 21-year bibliometric analysis
Zhongli Sun, Cun Liu, Yan Yao, et al.
Medicine (2025) Vol. 104, Iss. 10, pp. e41739-e41739
Open Access
Eco-Friendly Nanotherapeutics: Metallic Nanoparticles for Targeting Breast Cancer
Darakhshan Javaid, Shahid Yousuf Ganie, Syed Sanober Qadri, et al.
European Journal of Pharmacology (2025), pp. 177603-177603
Closed Access
Potential role of CFLAR in enhancing 5-FU sensitivity and modulating immune cell infiltration in breast cancer
Yuwei Sun, Weilun Fang, Jinwu Peng, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Biological function, regulatory mechanism, and clinical application of mannose in cancer
Haoyi Jin, Xi Liu, Hongxu Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188970-188970
Closed Access | Times Cited: 11
Advancing immunotherapy in triple negative breast Cancer: A novel multimodal theranostic nanoplatform integrating synergetic ferroptosis and photothermal therapy
Long Cheng, Yi‐Bo Qiu, Ling‐Yun He, et al.
Chemical Engineering Journal (2024) Vol. 485, pp. 150057-150057
Closed Access | Times Cited: 4
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges
Marco Palma
Vaccines (2025) Vol. 13, Iss. 4, pp. 344-344
Open Access
Dual-Regulated Biomimetic Nanocomposites For Promoted Tumor Photodynamic Immunotherapy
Li Liao, Yufei Liu, Xianhai Li, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma
Jie Liu, Wen‐Ping Lin, Yao Xiao, et al.
International Immunopharmacology (2023) Vol. 125, pp. 111128-111128
Closed Access | Times Cited: 9
Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy
Mohammad Hajimolaali, Farid Abedin Dorkoosh, Sophia G. Antimisiaris
Journal of Liposome Research (2024) Vol. 34, Iss. 4, pp. 671-696
Closed Access | Times Cited: 3
Review of immune checkpoint blockade and PD-L1 testing in breast cancer
Adelina Baltan, Simona Costache, Abeer M. Shaaban, et al.
Diagnostic histopathology (2024) Vol. 30, Iss. 2, pp. 110-122
Closed Access | Times Cited: 2
PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients
Junyue Zhang, Yiping Song, Ae-Ri Ahn, et al.
Cells (2024) Vol. 13, Iss. 17, pp. 1444-1444
Open Access | Times Cited: 2
Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment
Alina L. Capatina, Jodie R. Malcolm, Jack Stenning, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Gold nanorods with iron oxide dual-modal bioprobes in SERS-MRI enable accurate programmed cell death ligand-1 expression detection in triple-negative breast cancer
Ting Pan, Dinghu Zhang, Xiaoxia Wu, et al.
APL Bioengineering (2023) Vol. 7, Iss. 2
Open Access | Times Cited: 6
Development of nano-immunotherapy for cancer treatment: achievements and scopes
Akhil Raj, A. Chandra Babu, Vinoth Kumar Kothandan, et al.
Journal of Pharmaceutical Investigation (2023) Vol. 53, Iss. 6, pp. 827-844
Closed Access | Times Cited: 4
The prognostic value and potential immunotherapeutic efficacy of ACVR1 in treating gastric cancer
Hui Zhang, Ruiqi Liu, Yanrong Chen, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 1, pp. 63-85
Open Access | Times Cited: 1
Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy
Naresh Sah, Abdul Althaf Shaik, Ganesh Acharya, et al.
Receptors (2024) Vol. 3, Iss. 4, pp. 425-443
Open Access | Times Cited: 1
PD‑1/PD‑L1 inhibitor‑based immunotherapy in locally advanced or metastatic triple‑negative breast cancer: A meta‑analysis
Yonghui Chen, Liji Shi, Weihua Yin, et al.
Oncology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top